PRANA Biotechnology Presents New Benchmark Test to Assess Huntington's Disease Patients in Clinical Trials

Wed, 19 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Pluristem Therapeutics Provides Update on Clinical Status of IC Trials

Wed, 19 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HAIFA, Israel, June 19, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, provided an update today on the status of its clinical...

ChemoCentryx, Inc. Announces Completion of Target Enrollment of CCX140 Phase II Clinical Trial in Diabetic Nephropathy

Wed, 19 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MOUNTAIN VIEW, Calif., June 19, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced that it has completed the target enrollment of 270 patients in a Phase II clinical trial in diabetic nephropathy...

Takeda Pharmaceutical Co. Ltd. and Seattle Genetics, Inc. Highlight Post-Hoc Analysis Examining Progression-free Survival With ADCETRIS® (brentuximab vedotin) Versus Prior Therapy at the

Wed, 19 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LUGANO, Switzerland--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced data from a post-hoc analysis examining progression-free survival...

Oxygen Biotherapeutics, Inc. Reports Successful Completion of FDA Requested Immunocompetency Studies on Oxycyte®

Wed, 19 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (OBI) (NASDAQ: OXBT), is a development stage biomedical company currently focused on developing its perfluorocarbon-based intravenous oxygen...

Nektar Therapeutics (CA) Presents Positive Data From Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of

Wed, 19 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, June 19, 2013 /PRNewswire/ -- Nektar Therapeutics

Positive Survival Data for Bristol-Myers Squibb Company/AbbVie's Blood Cancer Drug

Tue, 18 Jun 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone...

Hyperion Therapeutics Announces RAVICTI and BUPHENYL Pharmacokinetic Analyses Reported in /i>

Tue, 18 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif., June 18, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that population pharmacokinetic (PK) modeling and dosing simulations were reported in...

OncoSec Medical Inc. Announces Completion of Enrollment of Phase II Metastatic Melanoma Trial

Tue, 18 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced the completion...

TWi Biotechnology Announces Completion of Patient Enrollment in Gout Flare Prophylaxis Phase II Trial for AC-201

Tue, 18 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TAIPEI, Taiwan, June 17, 2013 /PRNewswire/ -- TWi Biotechnology, Inc. today announced that it has completed...

MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) Initiates Phase II Clinical Trial of Pracinostat and Vidaza® in Frontline Myelodysplastic Syndrome

Tue, 18 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, June 18, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical...

iCo Therapeutics Inc. Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema

Tue, 18 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

VANCOUVER, June 18, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V...

Safety Fears Force Eli Lilly and Company to Halt Alzheimer's Trial

Mon, 17 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer's Disease

INDIANAPOLIS, ...

Janssen Research & Development's Ibrutinib Monotherapy Shows Efficacy in Patients With MCL or DLBCL

Mon, 17 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma

RARITAN...

Gilead Sciences, Inc. Announces Interim Phase 2 Data for Idelalisib Showing Response in Refractory Indolent Non-Hodgkin's Lymphoma

Mon, 17 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LUGANO, Switzerland--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from a single-arm, open-label Phase 2 study (Study 101-09) evaluating idelalisib (formerly GS-1101...

Celgene International S??rl's Apremilast Improves Oral Ulcer Pain From Behcet's Disease

Fri, 14 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Oral Apremilast Achieves Statistical Significance for Primary and Secondary Endpoints in a Phase II Trial in Patients with Behets Disease

BOUDRY, Switzerland--(BUSINESS...

Eli Lilly and Company, Incyte Corporation Arthritis Pill Effective in Mid-Stage Study

Thu, 13 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis

Leading HIV Researchers and Argos Therapeutics, Inc. Highlight Importance of Immunotherapy in HIV Eradication Efforts

Thu, 13 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

DURHAM, N.C., June 13, 2013 (GLOBE NEWSWIRE) -- In conjunction with the U.S. Food and Drug Administration's (FDA) June 14th Public Meeting on HIV Patient-Focused Drug Development and HIV Cure Research, leading...

XOMA (US) LLC Initiates Pilot Trial Studying Gevokizumab in Patients With Pyoderma Gangrenosum

Thu, 13 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BERKELEY, Calif., June 13, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced it has opened enrollment in a pilot study...

Immunomedics, Inc. Reports That UCB Group Announces New Results From Phase 2B Open-Label Extension Study Evaluating the Long-Term Effects of Epratuzumab in SLE

Thu, 13 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MORRIS PLAINS, N.J., June 13, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU),a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted...

Cempra Pharmaceuticals, Inc. Provides Guidance on the Clinical Program Required for Regulatory Approval for Solithromycin for Community-Acquired Bacterial Pneumonia (CABP)

Thu, 13 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CHAPEL HILL, N.C., June 13, 2013 /PRNewswire/ --Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company...

Teva Pharmaceutical Industries Limited and Active Biotech AB Report Positive Results From Phase IIa Study of Laquinimod in Active Lupus Nephritis

Wed, 12 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Jerusalem, Israel and Lund, Sweden, June 12(th), 2013 - Teva PharmaceuticalIndustries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI)announced today the results of a Phase IIa...

Biota Pharmaceuticals Initiates Phase 2 Trial of Laninamivir Octanoate for the Treatment of Influenza in Adults

Wed, 12 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ATLANTA, June 11, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced that it has commenced dosing in a multi-national, randomized, double blind, placebo controlled...

ViroPharma Incorporated Receives Orphan Drug Designation for Maribavir in Europe

Tue, 11 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

EXTON, Pa., June 11, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Commission...

Medicago, Inc. Receives Authorization From Health Canada and Commences Phase II Clinical Trial for an H5N1 Vaccine

Tue, 11 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

QUEBEC CITY, June 11, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical...

Bionomics Limited Completes Enrollment for BNC105 Phase II Renal Cancer Trial

Tue, 11 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ADELAIDE, South Australia, June 10, 2013 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) has completed enrolment into a randomized Phase II clinical trial testing the combination of BNC105 plus everolimus ...

Immunomedics, Inc. Release: 90Y-Epratuzumab Study Shows Improvement of Therapy Results Following R-CHOP

Tue, 11 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

VANCOUVER, British Columbia, June 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...

Ariad Pharmaceuticals, Inc. Announces Initiation of Phase 2 Trial of Ponatinib in Patients With Gastrointestinal Stromal Tumors

Tue, 11 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of the Phase 2 trial of Iclusig (ponatinib) in adult patients with metastatic and/or unresectable...

Superior Results in Foamix's Minocycline Foam Clinical Study: 71% Reduction in Inflammatory Lesions in 6 Weeks

Tue, 11 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

REHOVOT, Israel, June 11, 2013 -- /PRNewswire/ -- Foamix, a clinical stage specialty pharma company, has announced today the successful completion of its Minocycline foam Phase II clinical trial. The drug was...

Immune Response BioPharma Phase II IR103 Study Results IR103 REMUNEX Provides Maximum Effect

Mon, 10 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PRLog (Press Release) - Jun. 8, 2013 - NEW YORK -- Immune Response BioPharma, Inc., Today Publishes Phase II IR103 REMUNEX Study Results IR103-111 or CTN 203 Demonstrated...

Trigemina Initiates Phase II Clinical Trial of TI-001 for Chronic Migraine

Mon, 10 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SANTIAGO, Chile, June 10, 2013 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced...

BrainStorm Cell Therapeutics Inc. Treats 8th Patient in Phase IIa Trial; Completes Enrollment of Final 4 Patients

Mon, 10 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwired - June 10, 2013) - BrainStorm Cell Therapeutics (OTCQB: BCLI...

HemaQuest Completes Patient Enrollment in Phase 2b Clinical Study of HQK-1001 in Patients With Sickle Cell Disease

Mon, 10 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, June 10, 2013 /PRNewswire/ -- HemaQuest Pharmaceuticals, Inc. (HemaQuest), a biotechnology company focused...

BioAlliance Pharma Announces the Initiation of the Phase II Clinical Trial With Validive® in the United States

Mon, 10 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a Company dedicated to the development of orphan oncology products and supportive care products, announces the...

AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.)'s Future Depends on Triple-Negative Breast Cancer

Fri, 07 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Aveo Oncology (AVEO_) will succeed or fail depending on the potential for tivozanib to treat triple-negative breast cancer.For investors in Aveo, of which I am one, the wait for data from a phase II study...

Advaxis, Inc. Requests Orphan Drug Designation for Treatment of Cervical Cancer With ADXS-HPV

Fri, 07 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has submitted an Application...

ImmunoCellular Therapeutics, Ltd Announces Recommendation of Data Monitoring Committee to Continue ICT-107 Phase II Trial Following Interim Analysis

Fri, 07 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (ImmunoCellular) (NYSE MKT: IMUC) announced that the Data Monitoring Committee (DMC) has completed a pre-specified interim analysis of the ICT...

Esperion Therapeutics, Inc. Announces Positive Top-Line Results From Phase 2 Clinical Study of Novel Oral Therapy in Patients With Hypercholesterolemia and a History of Statin Intolerance

Fri, 07 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PLYMOUTH, Mich.--(BUSINESS WIRE)--Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol ...

Nuvilex's Cell Encapsulation Could Play Role in Multimodality Treatment of Cancer Patients

Thu, 06 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, NY--(Marketwired - June 06, 2013) - Nuvilex, Inc. (OTCQB: NVLX) has a technology in its cell encapsulation...

Idenix Pharmaceuticals, Inc. Announces Samatasvir (IDX719) Poster Presentations at the Conference

Thu, 06 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., June 6, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases...

RedHill Biopharma Ltd. Commences Patient Screening in a Phase IIa Clinical Trial With RHB-104 for Multiple Sclerosis

Wed, 05 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TEL-AVIV, Israel, June 5, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development...

NeuroVive Pharmaceutical AB: First Patient Recruited to Clinical Phase II Study for Treatment of Traumatic Brain Injury

Wed, 05 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: NeuroVive Pharmaceutical AB (publ)(STO:NVP), a leading mitochondrial medicine company, has recruited the first patient in a Phase IIa clinical trial to evaluate the...

Idera Pharmaceuticals, Inc. Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients With Moderate to Severe Plaque Psoriasis

Wed, 05 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals (NASDAQ: IDRA) today announced that it has initiated dosing in a randomized, double-blind, placebo-controlled Phase 2 trial of IMO-8400 in patients with...

BrainStorm Cell Therapeutics Inc. Submits Favorable Interim Safety Report for First Group of Patients in Its Phase IIa Dose-Escalating Trial

Wed, 05 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwired - June 05, 2013) - BrainStorm Cell Therapeutics (OTCQB: BCLI...

FDA Puts Pluristem Therapeutics Muscle Pain Drug Study on Clinical Hold

Tue, 04 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Pluristem to Receive Clinical-hold Notice From the U.S. FDA

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies...

Clovis Oncology Shares Almost Double on Cancer Drug Trial

Tue, 04 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Clovis Oncology's Rucaparib Demonstrates Encouraging Results from Ongoing Phase I/II Monotherapy Study in Patients with Solid Tumors

BOULDER, Colo.--(BUSINESS WIRE)-...

Ambit Biosciences Announces Presentation of Results From Phase 2 ACE Study of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology

Tue, 04 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CHICAGO, June 4, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) announced today that multiple...

Synta Pharmaceuticals's Lung Cancer Drug Struggles to Remain Relevant

Mon, 03 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

The efficacy of Synta Pharmaceuticals' (SNTA_) lung cancer drug ganetespib is weakening over time, which should raise even more concerns about the ongoing phase III clinical trial.

Snyta shares are...

AstraZeneca PLC's Drug is a First to Help Patients With Melanoma of the Eye

Mon, 03 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

New drug improves progression-free survival, shrinks tumors in rare cancer for first time

CHICAGO, JUNE 1, 2013 The experimental drug selumetinib is the first targeted...

Active Biotech AB's Project ANYARA Improved Overall Survival in a Subgroup of Renal Cell Cancer Patients

Mon, 03 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Lund (Sweden), June 3, 2013. Active Biotech (NASDAQ OMX NORDIC: ACTI) todaypresented overall survival (OS) and Progression Free Survival (PFS) data fromthe ANYARA Phase II/III study in renal cell...

EXINI and Active Biotech AB Present Impact of Tasquinimod on Bone Metastases as Measured by Bone Scan Index (BSI)

Mon, 03 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

EXINI Diagnostics AB (NASDAQ OMX First North: EXINI) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today presented Phase II retrospective follow-up data from the prostate cancer project with tasquinimod combined...

Positive Generex Biotechnology Corporation Data Underscores Cancer Immunotherapy Forecast Issued by

Mon, 03 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

WORCESTER, Mass. and TORONTO, May 31, 2013 /PRNewswire/ -- Generex Biotechnology Corporation...

Exelixis, Inc. Announces Presentation of Updated Phase 2 Data for Cabozantinib in Men With Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer

Mon, 03 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced the presentation of updated interim data from 144 docetaxel-pretreated patients with metastatic castration-resistant...

Cell Therapeutics, Inc. Reports Final Results From Cooperative Group and NCI-Sponsored Trial of Brostallicin in Patients With Metastatic Triple-Negative Breast Cancer

Mon, 03 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CHICAGO and SEATTLE, June 1, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) ...

Onconova Therapeutics Inc. Announces Presentation of Favorable Safety and Activity Data From Phase 2 Study of Oral Rigosertib in Lower Risk Myelodysplastic Syndromes

Mon, 03 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEWTOWN, Pa.--(BUSINESS WIRE)--Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced the presentation of safety and clinical activity data at the American Society of Clinical...

Ocular Therapeutix, Inc. Completes Enrollment in Phase II Study for Sustained Release Dexamethasone

Mon, 03 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. announced today it has completed enrollment for its sustained release dexamethasone (OTX-DP) in a Phase II study under an Investigational New Drug ...

Celator Pharmaceuticals, Inc. Announces New Data on Factors Associated With Outcomes in AML Patients Treated With CPX-351

Mon, 03 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PRINCETON, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing new and more effective therapies to treat cancer, today announced that a new analysis of...

Novartis Corporation Breakthrough Therapy LDK378 Shows a Marked Clinical Response in Patients With ALK+ Non-Small Cell Lung Cancer

Mon, 03 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

EAST HANOVER, N.J., June 3, 2013 /PRNewswire/ -- Novartis today announced data on its investigational compound LDK...

NewLink Genetics Announces Results From Two Clinical Studies With Indoximod

Mon, 03 Jun 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting

AMES, Iowa

FDA Lifts Hold on PharmAthene, Inc.'s Anthrax Vaccine Program

Fri, 31 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

FDA Lifts Clinical Hold on PharmAthene, Inc. (PIP)'s SparVax Anthrax Vaccine Program

ANNAPOLIS, Md., May 30, 2013 /PRNewswire/ ...

Alkermes plc Unveils Full Mid-Stage Data on Depression Drug

Fri, 31 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Alkermes Presents Positive Results from Phase 2 Clinical Study of ALKS 5461 in Major Depressive Diso

HOLLYWOOD, Fla. & DUBLIN--(BUSINESS WIRE)-- Alkermes plc (NAS: ALKS...

Medivir AB Release: An All-Oral Combination Phase II Study of Simeprevir and Samatasvir (IDX719) for the Treatment of Hepatitis C Virus Infection Initiated

Thu, 30 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Stockholm, Sweden Medivir AB (OMX: MVIR) today announced that IdenixPharmaceuticals Inc. has initiated a phase II clinical trial, called HELIX-1,evaluating an all-oral, direct-acting antiviral (DAA) HCV...

Novan Announces Promising Results of SB204 Clinical Study

Thu, 30 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

DURHAM, N.C., May 30, 2013 /PRNewswire/ -- Novan Therapeutics...

Medivir AB: an All-Oral Combination Phase II Study of Simeprevir and Samatasvir (IDX719) for the Treatment of Hepatitis C Virus Infection Initiated

Thu, 30 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HUDDINGE, Sweden & STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Medivir AB (OMX: MVIR) today announced that Idenix Pharmaceuticals Inc. has initiated a phase II clinical trial, called HELIX-1, evaluating an...

Euthymics Bioscience, Inc. Reports Top-Line Results from TRIADE Trial of Amitifadine for Major Depressive Disorder

Wed, 29 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Euthymics Bioscience, Inc. today announced top-line results from TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects), a phase 2b/3a clinical study designed to assess...

ASLAN Pharmaceuticals Pte Ltd Reports Positive Results for Gastric Cancer Treatment

Wed, 29 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD
May 28, 2013 -- Aslan Pharmaceuticals Pte reported that ASLAN001 was effective in a Phase II trial among heavily pre-treated gastric cancer patients. ASLAN001, a small-molecule...

Bavarian Nordic's CV-301 Cancer Immunotherapy Candidate Shows Promise in Colorectal Cancer

Wed, 29 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

KVISTGAARD, Denmark, May 29, 2013 - Bavarian Nordic A/S (OMX: BAVA) announcedtoday that promising data from a Phase 2 trial of its CV-301 cancerimmunotherapy candidate in patients with resected metastatic...

Targacept, Inc. Announces Initiation of Phase 2b Study of TC-5214 in Overactive Bladder

Wed, 29 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics , today announced the initiation of a Phase 2b clinical study...

Zealand Pharma and Helsinn Healthcare SA Announce Decision to Advance the Development of Elsiglutide into Phase IIb for the Prevention of Chemotherapy-Induced Diarrhea

Tue, 28 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Copenhagen, Denmark and Lugano, Switzerland, 2013-05-28 11:16 CEST (GLOBE NEWSWIRE) -- Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (Zealand) and its partner, the Swiss pharmaceutical group Helsinn, a...

La Jolla Pharmaceutical Company Releases Data Indicating GCS-100 May Improve Renal Function

Fri, 24 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, CA--(Marketwired - May 23, 2013) - La Jolla Pharmaceutical Company (OTCBB:

Clinical Trial Tests Targeting Prostate Cancer Treatment, University of Michigan Health System Study

Fri, 24 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ANN ARBOR, Mich., May 23, 2013 /PRNewswire-USNewswire/ -- Are certain drugs more effective against some types...

Regeneron Pharmaceuticals, Inc., Sanofi (France) Asthma Drug Seen as Potential Game Changer

Thu, 23 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine

PARIS and

OncoGenex Pharmaceuticals Inc. Announces Plans for the Initiation of the Cedar™ Clinical Trial Evaluating OGX-427 in Combination With Chemotherapy in Advanced Squamous Cell Lung Cancer

Thu, 23 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOTHELL, Wash. and VANCOUVER, British Columbia, May 23, 2013 /PRNewswire/ -- OncoGenex...

Lpath, Inc. Initiates Dosing in First Proof-of-Concept Trial of Anti-Cancer Drug, ASONEP

Thu, 23 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, May 23, 2013 (GLOBE NEWSWIRE) -- Lpath, Inc. (Nasdaq:LPTN), the industry leader in bioactive lipid-targeted therapeutics,has initiated dosing in a Phase 2a single-arm trial where ASONEP is being...

Merrimack Pharmaceuticals Inc. Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Exemestane in Breast Cancer

Thu, 23 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., May 23, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in a Phase 2 randomized, double blind clinical trial of...

Repros Therapeutics Inc. Release: FDA Recommends Running Phase 2b Trial of Proellex®-V in the Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids

Thu, 23 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

THE WOODLANDS, Texas, May 22, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) today announced it has met with the FDA regarding the clinical development of Proellex-V, the vaginally administered...

Lightlake Therapeutics Inc.??? Binge Eating Disorder Treatment Phase II Trial Results Presented at American Psychiatric Association 2013 Annual Meeting

Thu, 23 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LONDON--(BUSINESS WIRE)--Lightlake Therapeutics Inc. (OTCBB: LLTP) (the Company, We or Lightlake), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists...

Prosonix Initiates Phase 2 Clinical Study With PSX1002 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Wed, 22 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

OXFORD, England, May 22, 2013 -- /PRNewswire/ --
First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle engineering...

Oncolytics Biotech Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial

Wed, 22 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CALGARY, May 22, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY...

Agenus (Formerly known as Antigenics Inc. - Lexington, MA) Announces Initiation of Enrollment in National Cancer Institute-Sponsored Randomized Trial of Prophage G-200 Vaccine With Avastin in Treatment of Brain Tumors

Wed, 22 May 2013 12:00:00 AM GMT
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass., May 22, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) today announced enrollment has started for a large, randomized Phase 2 study of Prophage G-200 (Heat Shock Protein Peptide Complex...

BioSpace.com News

PRANA Biotechnology Presents New Benchmark Test to Assess Huntington's Disease Patients in Clinical Trials

Pluristem Therapeutics Provides Update on Clinical Status of IC Trials

ChemoCentryx, Inc. Announces Completion of Target Enrollment of CCX140 Phase II Clinical Trial in Diabetic Nephropathy

Takeda Pharmaceutical Co. Ltd. and Seattle Genetics, Inc. Highlight Post-Hoc Analysis Examining Progression-free Survival With ADCETRIS® (brentuximab vedotin) Versus Prior Therapy at the

Oxygen Biotherapeutics, Inc. Reports Successful Completion of FDA Requested Immunocompetency Studies on Oxycyte®

Nektar Therapeutics (CA) Presents Positive Data From Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of

Positive Survival Data for Bristol-Myers Squibb Company/AbbVie's Blood Cancer Drug

Hyperion Therapeutics Announces RAVICTI and BUPHENYL Pharmacokinetic Analyses Reported in /i>

OncoSec Medical Inc. Announces Completion of Enrollment of Phase II Metastatic Melanoma Trial

TWi Biotechnology Announces Completion of Patient Enrollment in Gout Flare Prophylaxis Phase II Trial for AC-201

MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) Initiates Phase II Clinical Trial of Pracinostat and Vidaza® in Frontline Myelodysplastic Syndrome

iCo Therapeutics Inc. Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema

Safety Fears Force Eli Lilly and Company to Halt Alzheimer's Trial

Janssen Research & Development's Ibrutinib Monotherapy Shows Efficacy in Patients With MCL or DLBCL

Gilead Sciences, Inc. Announces Interim Phase 2 Data for Idelalisib Showing Response in Refractory Indolent Non-Hodgkin's Lymphoma

Celgene International S??rl's Apremilast Improves Oral Ulcer Pain From Behcet's Disease

Eli Lilly and Company, Incyte Corporation Arthritis Pill Effective in Mid-Stage Study

Leading HIV Researchers and Argos Therapeutics, Inc. Highlight Importance of Immunotherapy in HIV Eradication Efforts

XOMA (US) LLC Initiates Pilot Trial Studying Gevokizumab in Patients With Pyoderma Gangrenosum

Immunomedics, Inc. Reports That UCB Group Announces New Results From Phase 2B Open-Label Extension Study Evaluating the Long-Term Effects of Epratuzumab in SLE

Cempra Pharmaceuticals, Inc. Provides Guidance on the Clinical Program Required for Regulatory Approval for Solithromycin for Community-Acquired Bacterial Pneumonia (CABP)

Teva Pharmaceutical Industries Limited and Active Biotech AB Report Positive Results From Phase IIa Study of Laquinimod in Active Lupus Nephritis

Biota Pharmaceuticals Initiates Phase 2 Trial of Laninamivir Octanoate for the Treatment of Influenza in Adults

ViroPharma Incorporated Receives Orphan Drug Designation for Maribavir in Europe

Medicago, Inc. Receives Authorization From Health Canada and Commences Phase II Clinical Trial for an H5N1 Vaccine

Bionomics Limited Completes Enrollment for BNC105 Phase II Renal Cancer Trial

Immunomedics, Inc. Release: 90Y-Epratuzumab Study Shows Improvement of Therapy Results Following R-CHOP

Ariad Pharmaceuticals, Inc. Announces Initiation of Phase 2 Trial of Ponatinib in Patients With Gastrointestinal Stromal Tumors

Superior Results in Foamix's Minocycline Foam Clinical Study: 71% Reduction in Inflammatory Lesions in 6 Weeks

Immune Response BioPharma Phase II IR103 Study Results IR103 REMUNEX Provides Maximum Effect

Trigemina Initiates Phase II Clinical Trial of TI-001 for Chronic Migraine

BrainStorm Cell Therapeutics Inc. Treats 8th Patient in Phase IIa Trial; Completes Enrollment of Final 4 Patients

HemaQuest Completes Patient Enrollment in Phase 2b Clinical Study of HQK-1001 in Patients With Sickle Cell Disease

BioAlliance Pharma Announces the Initiation of the Phase II Clinical Trial With Validive® in the United States

AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.)'s Future Depends on Triple-Negative Breast Cancer

Advaxis, Inc. Requests Orphan Drug Designation for Treatment of Cervical Cancer With ADXS-HPV

ImmunoCellular Therapeutics, Ltd Announces Recommendation of Data Monitoring Committee to Continue ICT-107 Phase II Trial Following Interim Analysis

Esperion Therapeutics, Inc. Announces Positive Top-Line Results From Phase 2 Clinical Study of Novel Oral Therapy in Patients With Hypercholesterolemia and a History of Statin Intolerance

Nuvilex's Cell Encapsulation Could Play Role in Multimodality Treatment of Cancer Patients

Idenix Pharmaceuticals, Inc. Announces Samatasvir (IDX719) Poster Presentations at the Conference

RedHill Biopharma Ltd. Commences Patient Screening in a Phase IIa Clinical Trial With RHB-104 for Multiple Sclerosis

NeuroVive Pharmaceutical AB: First Patient Recruited to Clinical Phase II Study for Treatment of Traumatic Brain Injury

Idera Pharmaceuticals, Inc. Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients With Moderate to Severe Plaque Psoriasis

BrainStorm Cell Therapeutics Inc. Submits Favorable Interim Safety Report for First Group of Patients in Its Phase IIa Dose-Escalating Trial

FDA Puts Pluristem Therapeutics Muscle Pain Drug Study on Clinical Hold

Clovis Oncology Shares Almost Double on Cancer Drug Trial

Ambit Biosciences Announces Presentation of Results From Phase 2 ACE Study of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology

Synta Pharmaceuticals's Lung Cancer Drug Struggles to Remain Relevant

AstraZeneca PLC's Drug is a First to Help Patients With Melanoma of the Eye

Active Biotech AB's Project ANYARA Improved Overall Survival in a Subgroup of Renal Cell Cancer Patients

EXINI and Active Biotech AB Present Impact of Tasquinimod on Bone Metastases as Measured by Bone Scan Index (BSI)

Positive Generex Biotechnology Corporation Data Underscores Cancer Immunotherapy Forecast Issued by

Exelixis, Inc. Announces Presentation of Updated Phase 2 Data for Cabozantinib in Men With Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer

Cell Therapeutics, Inc. Reports Final Results From Cooperative Group and NCI-Sponsored Trial of Brostallicin in Patients With Metastatic Triple-Negative Breast Cancer

Onconova Therapeutics Inc. Announces Presentation of Favorable Safety and Activity Data From Phase 2 Study of Oral Rigosertib in Lower Risk Myelodysplastic Syndromes

Ocular Therapeutix, Inc. Completes Enrollment in Phase II Study for Sustained Release Dexamethasone

Celator Pharmaceuticals, Inc. Announces New Data on Factors Associated With Outcomes in AML Patients Treated With CPX-351

Novartis Corporation Breakthrough Therapy LDK378 Shows a Marked Clinical Response in Patients With ALK+ Non-Small Cell Lung Cancer

NewLink Genetics Announces Results From Two Clinical Studies With Indoximod

FDA Lifts Hold on PharmAthene, Inc.'s Anthrax Vaccine Program

Alkermes plc Unveils Full Mid-Stage Data on Depression Drug

Medivir AB Release: An All-Oral Combination Phase II Study of Simeprevir and Samatasvir (IDX719) for the Treatment of Hepatitis C Virus Infection Initiated

Novan Announces Promising Results of SB204 Clinical Study

Medivir AB: an All-Oral Combination Phase II Study of Simeprevir and Samatasvir (IDX719) for the Treatment of Hepatitis C Virus Infection Initiated

Euthymics Bioscience, Inc. Reports Top-Line Results from TRIADE Trial of Amitifadine for Major Depressive Disorder

ASLAN Pharmaceuticals Pte Ltd Reports Positive Results for Gastric Cancer Treatment

Bavarian Nordic's CV-301 Cancer Immunotherapy Candidate Shows Promise in Colorectal Cancer

Targacept, Inc. Announces Initiation of Phase 2b Study of TC-5214 in Overactive Bladder

Zealand Pharma and Helsinn Healthcare SA Announce Decision to Advance the Development of Elsiglutide into Phase IIb for the Prevention of Chemotherapy-Induced Diarrhea

La Jolla Pharmaceutical Company Releases Data Indicating GCS-100 May Improve Renal Function

Clinical Trial Tests Targeting Prostate Cancer Treatment, University of Michigan Health System Study

Regeneron Pharmaceuticals, Inc., Sanofi (France) Asthma Drug Seen as Potential Game Changer

OncoGenex Pharmaceuticals Inc. Announces Plans for the Initiation of the Cedar™ Clinical Trial Evaluating OGX-427 in Combination With Chemotherapy in Advanced Squamous Cell Lung Cancer

Lpath, Inc. Initiates Dosing in First Proof-of-Concept Trial of Anti-Cancer Drug, ASONEP

Merrimack Pharmaceuticals Inc. Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Exemestane in Breast Cancer

Repros Therapeutics Inc. Release: FDA Recommends Running Phase 2b Trial of Proellex®-V in the Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids

Lightlake Therapeutics Inc.??? Binge Eating Disorder Treatment Phase II Trial Results Presented at American Psychiatric Association 2013 Annual Meeting

Prosonix Initiates Phase 2 Clinical Study With PSX1002 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Oncolytics Biotech Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial